Timing: Note when the pain occurs
[1] [5] While most GLP-1 medications are administered via subcutaneous injection (such as semaglutide, liraglutide, dulaglutide, or tirzepatide), with oral semaglutide (Rybelsus) as the only FDA-approved non-injectable option, transdermal patch delivery systems represent an emerging area of pharmaceutical development
Still, the appeal is obvious
Results Baseline characteristics (GLP-1RAs vs SGLT2 inhibitors) A total of 4,591,936 individuals with NAFLD and type 2 diabetes were identified
Twice daily works best for those with specific goals like aggressive anti-aging protocols or scar treatment where maximum peptide exposure accelerates results
Many patients who fall below a 30 BMI kg/m2 after one year on therapy might be good candidates to step down to less expensive therapies if their labs and clinical picture agree